Antimicrobial Stewardship

A clinician reviews the literature and offers some insights on the role of this antibiotic in bone, joint, and hardware infections.

A recently published study demonstrated the superior efficacy of cefepime–taniborbactam over meropenem for managing complicated urinary tract infections, suggesting a promising treatment option amid rising antibiotic resistance challenges.

ePOCT+, a digital clinician decision support tool, reduced outpatient antibiotic prescribing without adverse health outcomes, potentially mitigating development of antimicrobial resistance.

New vancomycin dosing regimens are proposed to improve outcome and minimize toxicity in overweight and obese patients with renal insufficiency.

Emerging treatment options for patients with persistently positive blood cultures with Methicillin-Susceptible Staphylococcus aureus (MSSA).

How the development of antimicrobial stewardship programs can be an effective strategy for beginning to reduce this critical timing for patients in ICUs.

Investigators studying over 4500 patients with gram-negative bacteremia see opportunities for earlier transition from IV to oral antibiotics.

This year saw the approval of new therapies as well as the continued evolution of time-to-treat infections and updated guidelines.

The current treatment pathway might need to evolve to adjust to rapid diagnostics and narrowing down the antibiotics to aid in optimal outcomes for sicker patients with gram-negative infections.

Three posters presented at ASHP Midyear 2023 delved deeper into the topic of antimicrobial stewardship programs and their impact on antibiotic resistance.

This bipartisan initiative highlights the need for a comprehensive approach to combat antimicrobial resistance (AMR), incorporating both antibiotic drug development and increased funding for stewardship programs.

Amikacin inhaled once daily for 3 days reduced risk of developing ventilator-associated pneumonia in placebo-controlled trial in critically ill.

A recent novel study found reduced mortality rates in combining these therapies in patients being treated for this specific bacteremia.

A study showed utilizing a PCR-based test can narrow therapy quicker and help in resolving these infections sooner.

A small study showed high efficacy for the same strain of Pseudomonas aeruginosa.

The proposed clinical benefits of de-escalation has contributed to its lukewarm adoption in some settings. This article looks at the challenges in measuring the impact of de-escalation, and the ongoing search for more meaningful metrics to evaluate the success of antimicrobial stewardship (AMS) programs.

The investigational agent, afabicin, was developed by private company, Debiopharm, and a clinician offers some insights on the therapy in these 2 therapeutic areas.

Empirical antibiotic therapy in diabetic foot ulcer infections increases hospitalization and prolonged symptoms in patients being treated for lower limb cellulitis are common. Two recent papers examine the need for effective communication, the importance of objective findings in cellulitis management, and the benefits of culture-based antibiotic therapy in diabetic foot ulcer cases.

Christian Sandrock, MD, MPH, FCCP, shares key takeaways on the antimicrobial resistant gram-negative infection space from ID week 2023.

An infectious disease expert reviews new treatment recommendations for patients suspected of having a polymicrobial infection.

Christian Sandrock, MD, MPH, FCCP, highlights key takeaways on approaching treatment of antimicrobial resistant gram-negative infections as presented in updated IDSA guidelines and ID week 2023.

Dr George Sakoulas provides insight on how single-dose agents fit into antimicrobial stewardship for soft tissue infections.

George Sakoulas, MD, provides key insights on the management of soft tissue infections including the role of single-dose agents and treating patients in an outpatient setting.

Dr Christian Sandrock evaluates the impact of 2023 updated IDSA guidelines on treatment decisions for patients with antimicrobial resistant gram-negative infections and for patients with multidrug-resistant pathogens.

Christian Sandrock, MD, MPH, FCCP, highlights key takeaways from 2023 Infectious Diseases Society of America (IDSA) updated guidelines for antimicrobial resistant gram-negative infections and how these updates have been implemented at his institution.